TOMI Environmental Solutions (TOMZ)
NASDAQ:TOMZ
Earnings Data
Report Date
May 19, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Cautiously optimistic. Management demonstrated clear commercial progress: product integrations, OEM partnerships, regulatory wins in food safety, meaningful increases in recurring revenue metrics and improved gross margins and operating expense discipline. However, these operational positives are offset by a sizable year-over-year revenue decline (-27.3% in 2025), a very low year-end cash balance (~$88k), ongoing net losses, and execution/timing risk converting a sizable pipeline into recognized revenue amid external headwinds and customer CapEx deferrals. The call conveys confidence in the technology and a credible path to recurring revenue, but near-term liquidity and timing risk remain material.Company Guidance
Commercial and Integration Milestones
SIS (SteraMist Integration System) achieved first commercial installation in June 2025 and reached 4 fully operational SIS enclosure installations by year-end; closed a $500,000 purchase contract in December with a global biopharmaceutical leader for sterile manufacturing pass-through fill boxes; pipeline for integration projects reported at $16 million and SteraMist iHP opportunity book at $20 million.
Strategic OEM and Distribution Partnerships
OEM partnerships (PBSC, ESCO, Steelco) embedding iHP into clean room enclosures and biosafety cabinets; first PBSC iHP pass-through collaboration exceeded cycle-speed expectations and a second PBSC project has begun; international distributor activity (e.g., ARES Scientific, TCA in U.K.) helping secure university and regional wins.
Recurring Revenue Traction and Backlog Growth
Backlog for TOMI Support Services increased 16% and BIT Solution backlog increased 24% in Q1 2026 vs Q1 2025; management highlights growing open BIT Solution orders and transition to recurring open order model as a strategic focus.
Q1 2026 Revenue Momentum vs Prior Year
Management stated Q1 2026 revenue is greater than Q1 2025, and cited concrete Q1 comparisons: solution sales rose to $429,413 from $299,000 (approximately +43.7%); support services rose to $253,390 from $73,279 (approximately +245.8%); iHP service (invoices + open orders) rose to $729,440 from $439,386 (approximately +66.1%).
Margin Improvement and Cost Discipline
Gross margin improved to ~55% in 2025 from 46% in 2024 (+9 percentage points); total operating expenses decreased ~10% year-over-year, reflecting disciplined cost management.
Improved Losses and Cash Flow Usage
Net loss improved to $3.7 million ($0.19 per share) in 2025 from $4.5 million ($0.22 per share) in 2024 (improvement of $0.8 million, ~17.8%); operating cash used improved to $1.2 million in 2025 from $1.4 million in 2024 (improvement of ~14.3%).
Regulatory and Market Approvals Supporting New Verticals
Late-2025 FDA approval of hydrogen peroxide as a direct food additive opened food-safety opportunities and engagement with large partners (e.g., Danone, Nestle); HSE/BPR approvals and recognition in U.K. and the Netherlands; pursuing EPA -4 and -5 labels and a tailored FCN for powdered infant formula.
Notable Customer Wins and Use-Cases
Cell & gene therapy manufacturer adopted SteraMist iHP for a commercial-scale pharmaceutical facility; NASA Johnson Space Center selected the technology for a biosecurity operation; a platinum eye-health customer expanded to 2 active facilities (5 machines each) with a third Berlin site trialing in June 2026; Algafeed partnership expands agricultural/food safety footprint.
Intellectual Property, Geographic Reach and Recognition
More than 30 utility and design patents through 2038; technology deployed in 40+ countries; honored as Disinfection Decontamination Products Company of the Year by MedTech Outlook; compliance on 3 safety vendor management platforms (adding a fourth).
Financing Tools Put in Place
Steps taken to address liquidity: $535,000 convertible note in 2025, $20 million equity line with Hudson Global Ventures (first draw ~$94,000 in Feb 2026), effective S3 shelf registration for up to $50 million, and engagement of Bancroft Capital to explore additional financing.
TOMZ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TOMZ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 31, 2026 | $0.55 | $0.58 | +5.24% |
Nov 14, 2025 | $0.82 | $0.75 | -8.54% |
Aug 14, 2025 | $0.94 | $0.92 | -2.13% |
May 08, 2025 | $0.84 | $0.86 | +2.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TOMI Environmental Solutions (TOMZ) report earnings?
TOMI Environmental Solutions (TOMZ) is schdueled to report earning on May 19, 2026, TBA (Confirmed).
What is TOMI Environmental Solutions (TOMZ) earnings time?
TOMI Environmental Solutions (TOMZ) earnings time is at May 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TOMZ EPS forecast?
Currently, no data Available